Factors Related to the Progression of Chronic Kidney Disease

March 16, 2011 updated by: Ankara Education and Research Hospital

The Impact of FGF23 and Klotho on Progression of Chronic Kidney Disease

Chronic kidney disease is a progressive disorder that has been influenced with many factors. Most of the patients has altered Ca P metabolism and these dis orders are the contributing factors of the disease progression. It has been recently documented that FGF23 and Klotho are the key factors of PTH secretion Ca-P metabolism. This study aimed to evaluate the impact of Klotho and FGF23 on the progression of stage 3-4 chronic kidney disease.

Study Overview

Status

Unknown

Conditions

Study Type

Observational

Enrollment (Anticipated)

90

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
      • Ankara, Turkey
        • Ankara Education and Research Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients diagnosed with non-diabetic chronic kidney disease between the ages of 18 and 65 years old.

Description

Inclusion Criteria:

  • Non-diabetic chronic kidney disease

Exclusion Criteria:

  • Presence of DM
  • Actively using calcium based phosphorus binder of vitamin D

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Progressive disease
Serum creatinin level rise more than 2 times
Non-progressive disease
Serum creatinin level rise less than 2 times

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Progression of kidney disease
Time Frame: continuous measurement of kidney functions 3 monthly for two years or until the outcome reached
Doubling of creatinin, requirement of renal replacement therapy
continuous measurement of kidney functions 3 monthly for two years or until the outcome reached

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evaluation of Ca P metabolism
Time Frame: 3 monthly for two years or until the outcome reached
Determination of Ca-P metabolism disorders.
3 monthly for two years or until the outcome reached

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Ankara Education and Research Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2008

Primary Completion (Anticipated)

May 1, 2011

Study Completion (Anticipated)

June 1, 2011

Study Registration Dates

First Submitted

March 16, 2011

First Submitted That Met QC Criteria

March 16, 2011

First Posted (Estimate)

March 17, 2011

Study Record Updates

Last Update Posted (Estimate)

March 17, 2011

Last Update Submitted That Met QC Criteria

March 16, 2011

Last Verified

January 1, 2011

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NEPH001

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Kidney Disease

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe